| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | UHNBreast | pan-cancer | AAC | -0.21 | 0.5 |
| mRNA | TPCA-1 | CTRPv2 | pan-cancer | AAC | -0.023 | 0.5 |
| mRNA | OSI-906 | CTRPv2 | pan-cancer | AAC | 0.025 | 0.5 |
| mRNA | staurosporine | CTRPv2 | pan-cancer | AAC | 0.051 | 0.5 |
| mRNA | Sildenafil | CTRPv2 | pan-cancer | AAC | -0.027 | 0.5 |
| mRNA | SGX-523 | CTRPv2 | pan-cancer | AAC | 0.026 | 0.5 |
| mRNA | prima-1 | CTRPv2 | pan-cancer | AAC | -0.022 | 0.5 |
| mRNA | BRD-K27188169:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.035 | 0.5 |
| mRNA | BCL-LZH-4 | CTRPv2 | pan-cancer | AAC | 0.036 | 0.5 |
| mRNA | barasertib | CTRPv2 | pan-cancer | AAC | -0.022 | 0.5 |